Metropolis Healthcare Ltd
NSE:METROPOLIS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 503.8
2 288
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Metropolis Healthcare Ltd
Metropolis Healthcare Ltd
Cost of Revenue
Metropolis Healthcare Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
Cost of Revenue
-₹2.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Dr Agarwal's Eye Hospital Ltd
BSE:526783
|
Cost of Revenue
-₹761.6m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-9%
|
|
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
Cost of Revenue
-₹1.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
Cost of Revenue
-₹4.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
|
Cost of Revenue
-₹654.4m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Krsnaa Diagnostics Ltd
NSE:KRSNAA
|
Cost of Revenue
-₹1.5B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
Metropolis Healthcare Ltd
Glance View
Metropolis Healthcare Ltd. owns and operates medical laboratories. The company is headquartered in Gurgaon, Haryana and currently employs 4,532 full-time employees. The company went IPO on 2019-04-15. The firm offers a range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and monitoring of the disease. The firm also offers analytical and support services to clinical research organizations for their clinical research projects. Its services include pathology testing services, corporate wellness, lab in hospitals and clinical research services. The firm offers a range of tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company owns a chain of diagnostic centers across India, South Asia, Africa and the Middle East. The firm has spread its footprint across 20 Indian states and over 210 cities.
See Also
What is Metropolis Healthcare Ltd's Cost of Revenue?
Cost of Revenue
-2.6B
INR
Based on the financial report for Jun 30, 2024, Metropolis Healthcare Ltd's Cost of Revenue amounts to -2.6B INR.
What is Metropolis Healthcare Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-7%
Over the last year, the Cost of Revenue growth was -3%. The average annual Cost of Revenue growth rates for Metropolis Healthcare Ltd have been 4% over the past three years , -7% over the past five years .
You don't have any saved screeners yet
